Phathom Pharmaceuticals, Inc.
PHAT
$14.60
-$0.14-0.95%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 64.98% | 17.10% | -13.84% | 6.43% | -97.90% |
| Total Depreciation and Amortization | -18.32% | -12.69% | -17.29% | 4.32% | 57.85% |
| Total Amortization of Deferred Charges | 31.58% | 46.80% | 46.84% | 11.13% | 8.67% |
| Total Other Non-Cash Items | -16.91% | -12.24% | -13.58% | -44.07% | 51.70% |
| Change in Net Operating Assets | -212.42% | -850.64% | -26.96% | -1,436.69% | 157.42% |
| Cash from Operations | 77.80% | 11.30% | -23.05% | -44.89% | -99.20% |
| Capital Expenditure | 38.64% | -110.87% | 55.00% | 98.95% | 95.31% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 38.64% | -110.87% | 55.00% | 98.95% | 95.31% |
| Total Debt Issued | -- | -- | -- | -88.33% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.76% | 280.95% | -- | -- | 938,800.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.22% | -99.68% | -- | -87.71% | 938,800.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -124.66% | -36.42% | -43.59% | -122.31% | 277.95% |